[
  {
    "ts": null,
    "headline": "Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.",
    "summary": "FEATURE  Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods.  The appeal of this group is its variety.",
    "url": "https://finnhub.io/api/news?id=6542f858d8626283ee7be88254122bfc8d08c3b6bc7a30476bc5a376269d59b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763573280,
      "headline": "Healthcare’s Momentum Gathers Steam. 3 Stocks With Bullish Charts.",
      "id": 137548640,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FEATURE  Healthcare stocks are recovering strongly as the year winds down. The is the best-performing of 11 major S&P sector funds over the past week, month, and three-month periods.  The appeal of this group is its variety.",
      "url": "https://finnhub.io/api/news?id=6542f858d8626283ee7be88254122bfc8d08c3b6bc7a30476bc5a376269d59b3"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics, Up 62% Since August, Lingers In Buy Zone On An Obesity Win",
    "summary": "Viking Therapeutics stock yo-yoed Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.",
    "url": "https://finnhub.io/api/news?id=2bc5be5ff885e86aad77661c4656dc1d97c500802f8baf2fe793126ba5df94e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763567480,
      "headline": "Viking Therapeutics, Up 62% Since August, Lingers In Buy Zone On An Obesity Win",
      "id": 137548641,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics stock yo-yoed Wednesday after the company said it overenrolled one of its final-phase studies for its weight-loss shot.",
      "url": "https://finnhub.io/api/news?id=2bc5be5ff885e86aad77661c4656dc1d97c500802f8baf2fe793126ba5df94e0"
    }
  },
  {
    "ts": null,
    "headline": "Head and Neck Squamous Cell Carcinoma Market Research Report 2025-2035: Sanofi, Sun Pharma, and Eli Lilly Lead Through the Development of New Drugs, Clinical Trials, Combination Treatment Strategies",
    "summary": "The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for targeted therapies. Key innovations like immunotherapies, precision medicine, and early detection biomarkers are reshaping the market landscape, improving patient outcomes, and driving therapy adoption. Developed and emerging markets see enhanced care accessibility, propelled by investments in cancer i",
    "url": "https://finnhub.io/api/news?id=7efa612c021be8aae39284c206c4d28d5789679318a454a347d6067537a12570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763564760,
      "headline": "Head and Neck Squamous Cell Carcinoma Market Research Report 2025-2035: Sanofi, Sun Pharma, and Eli Lilly Lead Through the Development of New Drugs, Clinical Trials, Combination Treatment Strategies",
      "id": 137548642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The global head and neck squamous cell carcinoma market is set for steady growth, driven by advancements in treatment options, increasing awareness of early cancer detection, and rising demand for targeted therapies. Key innovations like immunotherapies, precision medicine, and early detection biomarkers are reshaping the market landscape, improving patient outcomes, and driving therapy adoption. Developed and emerging markets see enhanced care accessibility, propelled by investments in cancer i",
      "url": "https://finnhub.io/api/news?id=7efa612c021be8aae39284c206c4d28d5789679318a454a347d6067537a12570"
    }
  },
  {
    "ts": null,
    "headline": "EXPLORING THE GLOBAL TRANSFORMATION OF HEALTH CARE WITH ELI LILLY's CEO DAVE RICKS",
    "summary": "T. Rowe Price, a global investment management firm and a leader in retirement, announced the latest episode of \"The Angle,\" an investment-themed podcast focused on timely topics shaping financial markets and featuring executives from some of the world's leading companies.",
    "url": "https://finnhub.io/api/news?id=209c8722886d7ecacc59f5b7101ef606e0a4d7f34b84f9fd55d70eb97ed89cc2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763564640,
      "headline": "EXPLORING THE GLOBAL TRANSFORMATION OF HEALTH CARE WITH ELI LILLY's CEO DAVE RICKS",
      "id": 137546895,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "T. Rowe Price, a global investment management firm and a leader in retirement, announced the latest episode of \"The Angle,\" an investment-themed podcast focused on timely topics shaping financial markets and featuring executives from some of the world's leading companies.",
      "url": "https://finnhub.io/api/news?id=209c8722886d7ecacc59f5b7101ef606e0a4d7f34b84f9fd55d70eb97ed89cc2"
    }
  },
  {
    "ts": null,
    "headline": "Stock Split Watch: Could This Unstoppable Growth Stock Be Next?",
    "summary": "Don't wait for a stock split to buy the stock, though.",
    "url": "https://finnhub.io/api/news?id=313182fbdb57a9e1746316d277a55f618a0ec9ccf916c4420a873ea89c6f4e32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763563980,
      "headline": "Stock Split Watch: Could This Unstoppable Growth Stock Be Next?",
      "id": 137548644,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Don't wait for a stock split to buy the stock, though.",
      "url": "https://finnhub.io/api/news?id=313182fbdb57a9e1746316d277a55f618a0ec9ccf916c4420a873ea89c6f4e32"
    }
  },
  {
    "ts": null,
    "headline": "Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies",
    "summary": "Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati",
    "url": "https://finnhub.io/api/news?id=a9142c91fda321638d70dad1ff94ceec52e79f8442e2e8633dc04412ae76c273",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763563920,
      "headline": "Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies",
      "id": 137546375,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati",
      "url": "https://finnhub.io/api/news?id=a9142c91fda321638d70dad1ff94ceec52e79f8442e2e8633dc04412ae76c273"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
    "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
    "url": "https://finnhub.io/api/news?id=930613e7be8028dfed893ae65e3fd828783bf46c3808cb88ce2e8451a64999ba",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763561280,
      "headline": "AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell?",
      "id": 137548645,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV rebounds after its Q3 dip as strong immunology and neuroscience growth offset Humira erosion and aesthetics weakness.",
      "url": "https://finnhub.io/api/news?id=930613e7be8028dfed893ae65e3fd828783bf46c3808cb88ce2e8451a64999ba"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk (NVO) To Lower US Prices of its Injectable Wegovy Obesity Drug",
    "summary": "​Novo Nordisk A/S (NYSE:NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo Nordisk A/S (NYSE:NVO) will lower the US prices of its injectable Wegovy obesity drug. The price reduction for injectable Wegovy follows the company’s earlier announcement on November 6, where it agreed with the US […]",
    "url": "https://finnhub.io/api/news?id=26c65539ff6d5e5fec70bb639eb45271d20ffc8c2221c6d3032200ed0c91db76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763554271,
      "headline": "Novo Nordisk (NVO) To Lower US Prices of its Injectable Wegovy Obesity Drug",
      "id": 137546376,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "​Novo Nordisk A/S (NYSE:NVO) is one of the Most Profitable Stocks to Buy Now. On November 17, Reuters reported that Novo Nordisk A/S (NYSE:NVO) will lower the US prices of its injectable Wegovy obesity drug. The price reduction for injectable Wegovy follows the company’s earlier announcement on November 6, where it agreed with the US […]",
      "url": "https://finnhub.io/api/news?id=26c65539ff6d5e5fec70bb639eb45271d20ffc8c2221c6d3032200ed0c91db76"
    }
  },
  {
    "ts": null,
    "headline": "Viking: Playfield Has Changed, Downgrading To Hold After A Strong Run",
    "summary": "Discover why Viking Therapeutics, Inc. surged 50% as GLP-1 market buzz and strong VK2735 results renew investor optimism. Click for my VKTX update.",
    "url": "https://finnhub.io/api/news?id=da2da9d88a16c3efbfa16773a5f12f9fcf0983a3373ba62a9088c6785eef25b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763553214,
      "headline": "Viking: Playfield Has Changed, Downgrading To Hold After A Strong Run",
      "id": 137547708,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2165521222/image_2165521222.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover why Viking Therapeutics, Inc. surged 50% as GLP-1 market buzz and strong VK2735 results renew investor optimism. Click for my VKTX update.",
      "url": "https://finnhub.io/api/news?id=da2da9d88a16c3efbfa16773a5f12f9fcf0983a3373ba62a9088c6785eef25b0"
    }
  },
  {
    "ts": null,
    "headline": "Lilly announces plans to open Lilly Gateway Labs site in Philadelphia",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia, bringing its distinctive model of scientific partnership to a city known for shaping the future of medicine.",
    "url": "https://finnhub.io/api/news?id=79735e43ab40f5692bf575bca426c04032471d2f13a78f64881596cb6ee08625",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763552700,
      "headline": "Lilly announces plans to open Lilly Gateway Labs site in Philadelphia",
      "id": 137546378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced plans to open a new Lilly Gateway Labs (LGL) site in Philadelphia, bringing its distinctive model of scientific partnership to a city known for shaping the future of medicine.",
      "url": "https://finnhub.io/api/news?id=79735e43ab40f5692bf575bca426c04032471d2f13a78f64881596cb6ee08625"
    }
  },
  {
    "ts": null,
    "headline": "Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia",
    "summary": "Breakthrough Properties today announced that it has partnered with Eli Lilly and Company (Lilly) to launch Lilly Gateway Labs at Breakthrough at 2300 Market Street in Philadelphia. This new partnership provides innovative biotech companies comprehensive access to move-in ready labs, fully-equipped workspaces, and amenities they need to succeed and grow.",
    "url": "https://finnhub.io/api/news?id=5b63e1faffb6144b03668682a77d8493eb75c097f299e7df8637c4e8f8edb3a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763552700,
      "headline": "Breakthrough Properties and Eli Lilly and Company Partner to Bring Lilly Gateway Labs to Newly-Developed 2300 Market Street in Philadelphia",
      "id": 137546377,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Breakthrough Properties today announced that it has partnered with Eli Lilly and Company (Lilly) to launch Lilly Gateway Labs at Breakthrough at 2300 Market Street in Philadelphia. This new partnership provides innovative biotech companies comprehensive access to move-in ready labs, fully-equipped workspaces, and amenities they need to succeed and grow.",
      "url": "https://finnhub.io/api/news?id=5b63e1faffb6144b03668682a77d8493eb75c097f299e7df8637c4e8f8edb3a6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gains from Big Earnings, Bullish Inflows",
    "summary": "Eli Lilly and Company (LLY) shares up 15,892% since Big Money bought big in 1990.",
    "url": "https://finnhub.io/api/news?id=b73ce39018ca03814bd6d4bb2921c67098c2e1f419f05cef50202580d121cc4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763552656,
      "headline": "Eli Lilly Gains from Big Earnings, Bullish Inflows",
      "id": 137548646,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (LLY) shares up 15,892% since Big Money bought big in 1990.",
      "url": "https://finnhub.io/api/news?id=b73ce39018ca03814bd6d4bb2921c67098c2e1f419f05cef50202580d121cc4c"
    }
  },
  {
    "ts": null,
    "headline": "Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution",
    "summary": "Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are awaited.",
    "url": "https://finnhub.io/api/news?id=c7bd85a00fcb9ac9ae5168533838407fc8a37c7c0f99f151be70eb61289d9084",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763552212,
      "headline": "Olema Pharmaceuticals: Shares Double On Roche's MBC Data - I Preach Caution",
      "id": 137547681,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2230865518/image_2230865518.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are awaited.",
      "url": "https://finnhub.io/api/news?id=c7bd85a00fcb9ac9ae5168533838407fc8a37c7c0f99f151be70eb61289d9084"
    }
  },
  {
    "ts": null,
    "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
    "summary": "These stocks both have advanced in the double-digits in recent months.",
    "url": "https://finnhub.io/api/news?id=8b75acbfbf9c4a17b90fc988cb5c2820826da69a7ce6e9dc2fc13da531e9a82a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763550300,
      "headline": "Missed Out on Eli Lilly? 2 Healthcare Stocks With Big Catalysts on the Horizon.",
      "id": 137546379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These stocks both have advanced in the double-digits in recent months.",
      "url": "https://finnhub.io/api/news?id=8b75acbfbf9c4a17b90fc988cb5c2820826da69a7ce6e9dc2fc13da531e9a82a"
    }
  },
  {
    "ts": null,
    "headline": "Why VYM Is Not A Good Alternative To SCHD",
    "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
    "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763542800,
      "headline": "Why VYM Is Not A Good Alternative To SCHD",
      "id": 137546014,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1990349253/image_1990349253.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover top US dividend ETFs: Compare VYM vs SCHD for stable yields, growth, and income strategies amid market shifts.",
      "url": "https://finnhub.io/api/news?id=c5563932ada62abe02044bdccad8e3c11fead5a0c21a2908596d047781c4da32"
    }
  },
  {
    "ts": null,
    "headline": "The Zacks Analyst Blog Highlights Microsoft, Amazon.com and Eli Lilly",
    "summary": "Microsoft posts strong cloud-fueled Q1 results as Azure surges and AI momentum builds, even as capacity limits pose near-term revenue constraints.",
    "url": "https://finnhub.io/api/news?id=9eaea1ea3e2a877984250c74368f1b23645562b44d8923702b82930d07607002",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763542020,
      "headline": "The Zacks Analyst Blog Highlights Microsoft, Amazon.com and Eli Lilly",
      "id": 137546380,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Microsoft posts strong cloud-fueled Q1 results as Azure surges and AI momentum builds, even as capacity limits pose near-term revenue constraints.",
      "url": "https://finnhub.io/api/news?id=9eaea1ea3e2a877984250c74368f1b23645562b44d8923702b82930d07607002"
    }
  },
  {
    "ts": null,
    "headline": "IHF: Healthcare Dashboard For November",
    "summary": "Healthcare providers are undervalued. Click here to find out which stocks are the cheapest and if the IHF ETF is a risky buy.",
    "url": "https://finnhub.io/api/news?id=0d974aeabb97e2367c7108b67f02b0013f313b2c9fe487e2f2d2e8eedd5b54a0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763535660,
      "headline": "IHF: Healthcare Dashboard For November",
      "id": 137545449,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2211393518/image_2211393518.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Healthcare providers are undervalued. Click here to find out which stocks are the cheapest and if the IHF ETF is a risky buy.",
      "url": "https://finnhub.io/api/news?id=0d974aeabb97e2367c7108b67f02b0013f313b2c9fe487e2f2d2e8eedd5b54a0"
    }
  },
  {
    "ts": null,
    "headline": "2 High-Flying Stocks with Exciting Potential and 1 We Find Risky",
    "summary": "Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.",
    "url": "https://finnhub.io/api/news?id=1f015a3ce6842195f7d90c5a1ce5ab58c0a1d312e187f5bbb634bb45ccbeb5fa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763527069,
      "headline": "2 High-Flying Stocks with Exciting Potential and 1 We Find Risky",
      "id": 137546381,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly susceptible to drawdowns when market sentiment shifts.",
      "url": "https://finnhub.io/api/news?id=1f015a3ce6842195f7d90c5a1ce5ab58c0a1d312e187f5bbb634bb45ccbeb5fa"
    }
  },
  {
    "ts": null,
    "headline": "JP Morgan Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "summary": "JP Morgan Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=6e3604e3665c8d7b4d4b78685e6c5801b46e6f379635a2fc4a3983d355e8b0c3",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763510596,
      "headline": "JP Morgan Maintains Eli Lilly and (LLY) Overweight Recommendation",
      "id": 137541591,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6e3604e3665c8d7b4d4b78685e6c5801b46e6f379635a2fc4a3983d355e8b0c3"
    }
  }
]